TGF-beta activated kinase 1 (TAK1) is a drugable target for pancreatic cancer (PC)

TGF-beta activated kinase 1 (TAK1) is a drugable target for pancreatic cancer (PC

TGF-beta-activated kinase 1 (TAK1) is an in vivo druggable target for reverting pancreatic cancer chemoresistance

TGF-beta-activated kinase 1 (TAK1) is an in vivo druggable target for reverting pancreatic cancer chemoresistanc

The novel poly(ADP-ribose) polymerase (PARP)-1 inhibitor, BSI-401, has anti tumor activity and potentiates oxaliplatin cytotoxic activity in human pancreatic cancer

The novel poly(ADP-ribose) polymerase (PARP)-1 inhibitor, BSI-401, has anti tumor activity and potentiates oxaliplatin cytotoxic activity in human pancreatic cance

Targeting transforming growth factor beta (TGFbeta) type I receptor kinase activity: a therapeutic approach to suppress metastatic processes in human pancreatic cancer (HPC)

Targeting transforming growth factor beta (TGFbeta) type I receptor kinase activity: a therapeutic approach to suppress metastatic processes in human pancreatic cancer (HPC

Anti- VEGF treatment resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype

Anti- VEGF treatment resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotyp

Pro-inflammatory factors secreted by pancreatic cancers with evasive resistance to anti-VEGF treatment contribute to malignant progression by inducing EMT

Pro-inflammatory factors secreted by pancreatic cancers with evasive resistance to anti-VEGF treatment contribute to malignant progression by inducing EM

TGF-beta-activated Kinase 1 (TAK1) is a therapeutic target modulating pancreatic cancer chemoresistance

TGF-beta, TAK1, chemoresistanc

Serum CA 19-9 level as a surrogate marker for prognosis in locally advanced pancreatic cancer (LAPC).

Serum CA 19-9 level as a surrogate marker for prognosis in locally advanced pancreatic cancer (LAPC)